Latest News

Background: There is emerging evidence that radiographic progression-free survival (rPFS) is highly correlated with overall survival (OS), potentially serving as an indicator of treatment outcome for castration-resistant prostate cancer (CRPC). The objective of this study is to assess rPFS and prostate specific antigen (PSA) response in sequential treatment using androgen signaling inhibitors (ASIs) including abiraterone […]

The relation between prostate-specific antigen (PSA) and other relevant prebiopsy information is often combined in a risk calculator (RC). If the setting for RC use differs from that in which it was developed, there is a risk of making clinical decisions based on incorrect estimates of the absolute risk. The ERSPC-MRI RC predicts clinically significant […]

PROPHET is a prospective study in order to clarify a diagnostic impact of laboratory-based and prostate volume-adjusted [-2]proPSA-related indices on prostate cancer and a clinically significant prostate cancer in the PSA below 10 ng/mL. Between April 2015 and March 2017, 421 men aged 50 to 79 in the PSA range above age-specific cut-offs and below […]

Management of patients with a very high prostate-specific antigen (PSA) level (≥98.0 ng/mL) but clinically localized (N0M0) prostate cancer is challenging. This study sought to determine practice patterns and outcomes among these patients. A total of 748,825 patients with prostate cancer from 2004 through 2012 were identified using the National Cancer Database. These patients were […]

Intratumoral genetic heterogeneity and the role of metabolic reprogramming in renal cell carcinoma (RCC) have been extensively documented. However, the distribution of these metabolic changes within the tissue has not been explored. We report on the first-in-human in vivo non-invasive metabolic interrogation of RCC using hyperpolarized carbon-13 (13C) magnetic resonance imaging (HP-MRI) and describe the […]

Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors, although no prospective data regarding their use in this setting exist. Axitinib is a VEGF-R inhibitor with clinical data supporting increased activity with dose […]

Indications for partial nephrectomy (PN) have expanded to include larger tumors. Compared with radical nephrectomy (RN), PN reduces the risk of chronic kidney disease but is associated with higher morbidity. To explore whether the benefit of PN (preservation of estimated glomerular filtration rate [eGFR] ≥60ml/min/1.73m2 1yr postoperatively) over RN is offset by higher morbidity for […]

A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma Condition: Urothelial Carcinoma Purpose: The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma. Study Type: Observational Clinical Trials Identifier […]

Diane Newman: Welcome. I’m Diane Newman. I’m a nurse practitioner and continence nurse specialist. I am the editor of the Pelvic Health Center at UroToday, a website that specializes in urologic conditions. I’m also a practitioner at the University of Pennsylvania in the division of urology. I’m here today with a very important guest, who […]

This retrospective study of community practices assessed the adoption of active surveillance (AS) between January 2013 and March 2014 in 9 geographically dispersed community urology practices including more than 235 urologists. The authors defined AS according to documentation of AS within 6 months of prostate cancer (PCa) diagnosis or absence of treatment with continuous follow-up, […]